Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions
Eosinophilic EsophagitisCeliac Disease
Interventions
BIOLOGICAL

CALY-002

1-hour intravenous infusion

BIOLOGICAL

Placebo

1-hour intravenous infusion

Trial Locations (13)

Unknown

Cliniques Universitaires Saint-Luc - Hospital, Brussels

UZ Leuven, Leuven

Tampere University Hospital, Tampere

Charite, Berlin

Universitatsklinikum Erlangen - Hospital, Erlangen

Universitätsklinikum Freiburg - Hospital, Freiburg im Breisgau

Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Hospital, Mainz-GE

Klinikum rechts der Isa der Technischen Universitaet Muenchen - Hospital, Munich

AMC, Amsterdam

Ziekenhuis Rijnstate - Hospital, Arnhem

Maastricht University Medical Center - Hospital, Maastricht

Alesund Hospital, Ålesund

Oslo University Hospital HF, Oslo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Calypso Biotech BV

INDUSTRY